AstraZeneca-Oxford vaccine effective 70% on average
The coronavirus vaccine candidate developed by AstraZeneca and Oxford University is about 70% effective on average in preventing the virus, according to the latest clinical trial results released on Monday.
On regimen tested saw the vaccine’s effectiveness jump to 90%, namely when patients were first administered a half dose, followed by a full dose one month later. Meanwhile, AstraZeneca said that its COVID-19 vaccine can be stored, transported, and handled at normal refrigerated conditions between 2 and 8 degrees Celsius, unlike Pfizer’s. Moderna’s vaccine candidate also appears to have this advantage.
Commenting on the fresh results, Pascal Soriot, chief executive officer at AstraZeneca, said: “Today marks an important milestone in our fight against the pandemic. This vaccine’s efficacy and safety confirm that it will be highly effective against COVID-19 and will have an immediate impact on this public health emergency.”
Get involved!
Comments